Clinical Trials Logo

Chronic Idiopathic Urticaria clinical trials

View clinical trials related to Chronic Idiopathic Urticaria.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04175704 Not yet recruiting - Clinical trials for Chronic Idiopathic Urticaria

Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria

Start date: December 30, 2023
Phase: Phase 1
Study type: Interventional

The study is to evaluate the profiles of safety, tolerability, pharmacokinetics, and pharmacodynamics of UB-221. In this study, safety profile of UB-221 and maximum tolerated dose (MTD) is to be investigated using sentinel dosing strategy. The starting dose of 0.2 mg/kg is selected based on the evaluation and comparison of various approaches including NOAEL, MABEL (minimum anticipated biological effect level), and experiences from other anti-IgE mAb drugs in development.

NCT ID: NCT02166151 Not yet recruiting - Clinical trials for Chronic Idiopathic Urticaria

Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria

Start date: July 2014
Phase: Phase 3
Study type: Interventional

The study is designed to assess the efficacy and safety of monthly injections of Omalizumab 150 mg for 3 consecutive months, in patients with chronic idiopathic urticaria, unresponsive to convetional therapy by antihistamins or oral corticosteroids.